Neal Walker - Apr 21, 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
President and CEO, Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Apr 21, 2022
Transactions value $
-$1,060,701
Form type
4
Date filed
4/25/2022, 05:13 PM
Previous filing
Mar 14, 2022
Next filing
Jun 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Sale -$381K -25K -1.9% $15.24 1.29M Apr 21, 2022 Direct F1, F2
transaction ACRS Common Stock Sale -$376K -25K -1.94% $15.04 1.27M Apr 22, 2022 Direct F1, F3
transaction ACRS Common Stock Sale -$304K -20K -1.58% $15.18 1.25M Apr 25, 2022 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2022.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.